^
Association details:
| Biomarker: | SLAMF6 expression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | SGN-CD352A (DNA replication inhibitor, CD352-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 1195: SGN-CD352A: A novel humanized anti-CD352 antibody-drug conjugate for the treatment of multiple myeloma
Excerpt:
We observed CD352 expression on the surface of malignant plasma cells in 87% (13/15) of human multiple myeloma patient samples...SGN-CD352A demonstrated potent cytotoxic activity (EC50 values 6.6 - 52.6 pM) against a panel of human myeloma and lymphoma cell lines, with efficient cancer cell killing observed at CD352 expression levels...In summary, CD352 is a newly validated multiple myeloma tumor antigen and the novel PBD dimer ADC SGN-CD352A shows potent antitumor activity against cell line models of MM at clinically relevant doses.
DOI:
https://doi.org/10.1158/1538-7445.AM2016-1195
